Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous retrovirus group E member 1 (ERVE-1)
- Target
- ERVE-1
- Molecular classification
- Retroviral-like element, Transposon, Endogenous retrovirus, Other
01
Overview
Endogenous retrovirus group E member 1 (ERVE-1) is a genomic locus derived from ancient retroviral infection events, classified within the HERV-E family. ERVE-1 contains remnants of retroviral genes, such as gag, pol, and env, and is flanked by long terminal repeats (LTRs), typical of retroviral integrations. While the majority of HERV elements are nonfunctional due to mutations, ERVE-1 has been shown to express specific transcripts in tissues like the pancreas and thyroid, although its protein products are typically not fully functional and may serve only regulatory roles. ERVE-1 is not recognized as a receptor, enzyme, or another classical therapeutic target, but may influence the expression of nearby genes through its regulatory sequences. To date, there are no drugs or biomarker roles specifically attributed to ERVE-1, and it is not associated with known safety concerns or therapeutic challenges.
- Other names
- HERV-E1HERVE1TCONS_00025599Endogenous retrovirus group E, member 1
02
Mechanism of action
Not applicable. No drugs with known mechanism of action targeting ERVE-1.
03
Biological functions
Genomic element; may contain retroviral gag, pol, and env genesOccasional tissue-specific expression of retroviral transcripts (e.g., pancreas, thyroid)Possible involvement as regulatory elements (enhancers or promoters for nearby genes)Other
04
Disease associations
Other (no well-established direct disease roles for ERVE-1 specifically)Endogenous retroviruses as a group are relevant in: Cancer (some HERVs overexpressed in tumors)AutoimmunityInfectionPlacental biologyBut ERVE-1 itself does not currently have a clearly defined disease association
05
Safety considerations
None specific to ERVE-1. Theoretically, activation of HERV elements can contribute to genome instability or immune activation, but evidence for ERVE-1 is lacking
06
Interacting drugs
None currently identified for ERVE-1. No known drugs directly target this element
07
Biomarkers
None established for ERVE-1. Some HERV family members in general may serve as expression biomarkers, but not ERVE-1 specifically
Beyond the preview
Go deeper on Endogenous retrovirus group E member 1 (ERVE-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous retrovirus group E member 1 (ERVE-1).